RhumbLine Advisers’s Atossa Therapeutics ATOS Stock Holding History

RhumbLine Advisers’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-8,657	Closed	-$87.4K	–	4149
2025 Q1	$87.4K	Buy	8,657 +509	+6%	+$6.18K	﹤0.01%	3436
2024 Q4	$115K	Sell	8,148 -55	-0.7%	-$1.07K	﹤0.01%	3438
2024 Q3	$187K	Sell	8,203 -805	-9%	-$16.3K	﹤0.01%	3269
2024 Q2	$161K	Buy	+9,008	New	+$199K	﹤0.01%	3346
2022 Q2	–	Sell	-9,460	Closed	-$177K	–	3103
2022 Q1	$177K	Buy	9,460 +685	+8%	+$13.9K	﹤0.01%	2785
2021 Q4	$211K	Sell	8,775 -224	-2%	-$8.2K	﹤0.01%	2819
2021 Q3	$440K	Buy	8,999 +308	+4%	+$17.9K	﹤0.01%	2604
2021 Q2	$824K	Buy	+8,691	New	+$460K	﹤0.01%	2333

Other funds holding ATOS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

RhumbLine Advisers's ATOS Position: Q2 2025 in Review

RhumbLine Advisers sold out of Atossa Therapeutics (ATOS) in Q2 2025, closing a stake of 8,657 shares — an estimated $87.4K sold.

RhumbLine Advisers first reported a position in ATOS in Q2 2021 and held it in 8 quarters. The position peaked at $824K in Q2 2021. 84 funds tracked by Wall St. Rank hold ATOS as of Q2 2025.

RhumbLine Advisers reported no remaining Atossa Therapeutics position as of Q2 2025 after selling out during the quarter.
RhumbLine Advisers sold 8,657 Atossa Therapeutics shares in Q2 2025, an estimated $87.4K.
RhumbLine Advisers first reported a position in Atossa Therapeutics in Q2 2021 and held it in 8 quarters.
RhumbLine Advisers's Atossa Therapeutics position peaked at $824K in Q2 2021.
84 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.